Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

GENETICALLY MODIFIED TISSUE ENGINEERED IN VITRO HUMAN MODELS

Award Number: R44GM084551
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2009
PERIOD OF PERFORMANCE END DATE: 10/30/2014

Group Awards By:

View Award Description

GENETICALLY MODIFIED TISSUE ENGINEERED IN VITRO HUMAN MODELS - DESCRIPTION (provided by applicant): The goal of the current proposal is to apply state-of-the-art gene modification technology, including lentiviral delivery systems and RNA interference (RNAi) technology, to produce commercially available tissue engineered in vitro human models with advanced functional features. The commercial products to be developed will consist of organotypic 3-D skin and airway epithelial models that will be utilized for toxicology testing in consumer product/drug development, immunology and basic research applications. Advanced features that will be incorporated into the genetically modified tissue engineered in vitro human models will include: 1) gene activity reporter functions for monitoring the activity of various cel signaling pathways of toxicological, immunological or developmental significance; and 2) genetically modified tissue engineered in vitro human models with knockdown or over-expression of specific genetic functions. During the Phase I project, the feasibility of producing these models was established by development of organotypic skin and airway models with reporter functions for monitoring activity of NF B and Nrf2 transcription factors (TFs). These TFs are involved in inflammatory and antioxidant response signaling pathways, respectively. Induction of reporter activity was evaluated qualitatively by epifluorescence microscopy of green fluorescent protein (GFP), and quantitatively by measurement of luciferase activity in tissue extracts. Significant progress was also made in development of gene knockdown models. Epidermal cells were genetically modified to allow inducible knockdown of interleukin-1 IL-1 , a cytokine that plays an important role in epithelial inflammation, wound healing and disease states induced by environmental agents. Knockdown of IL-1 gene and protein expression of 72 % was achieved. Incorporation of these cells into organotypic models and further functional testing is in progress. A panel of 14 organotypic skin and airway epithelial TF reporter models for monitoring activity of cell signaling pathways of toxicological, immunological or developmental significance will be produced during the Phase II project. The models will be assembled into commercial products consisting of various combinations and configurations including high throughput 96-well formats, and validated with a comprehensive set of reference chemicals. These models will allow mechanistic toxicological evaluation of industrial chemicals, consumer product ingredients or environmental agents. The commercial models are intended for use by chemical producers, consumer product and cosmetic manufacturers, pharmaceutical companies, as well as industrial, governmental and academic environmental toxicologists and pharmaceutical researchers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $483,227 )
2013	2013	MATTEK CORPORATION	200 HOMER AVENUE	ASHLAND	MA	01721	MIDDLESEX	USA	Biomedical Research and Research Training	000	3	4/19/2013	NON-COMPETING CONTINUATION	$483,227
														Subtotal = $483,227

Issue Date FY: 2012 ( Subtotal = $483,227 )
2012	2012	MATTEK CORPORATION	200 HOMER AVENUE	ASHLAND	MA	01721	MIDDLESEX	USA	Biomedical Research and Research Training	000	2	5/4/2012	COMPETING CONTINUATION	$483,227
														Subtotal = $483,227

Grand Total All Awards = $966,454

Top

All Categories

About

Search

Reports

Data Submission

Award Information

GENETICALLY MODIFIED TISSUE ENGINEERED IN VITRO HUMAN MODELS

Award Number: R44GM084551

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2009

PERIOD OF PERFORMANCE END DATE: 10/30/2014

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer